Edwards Lifesciences (EW, Financial) has unveiled promising eight-year data from a pivotal study highlighting the superior performance of its aortic surgical valves using Resilia tissue technology. The results indicate significantly better long-term outcomes for patients compared to those receiving non-Resilia tissue bioprosthetic valves.
The findings, presented at the Heart Valve Society Annual Meeting, represent the first extensive, propensity-matched analysis involving 947 patients who underwent surgery for aortic valve replacement. The study underscores the advantages of Resilia tissue over alternative tissue types, with participants experiencing notably lower rates of structural valve deterioration.
Moreover, patients with Resilia-treated valves demonstrated a reduced need for reoperation due to structural valve deterioration, showcasing the durability and enhanced performance of the Resilia technology. These results contribute to the growing body of evidence supporting the long-term efficacy and patient benefits of Edwards Lifesciences' proprietary technology.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 27 analysts, the average target price for Edwards Lifesciences Corp (EW, Financial) is $79.50 with a high estimate of $90.00 and a low estimate of $61.00. The average target implies an upside of 11.14% from the current price of $71.53. More detailed estimate data can be found on the Edwards Lifesciences Corp (EW) Forecast page.
Based on the consensus recommendation from 33 brokerage firms, Edwards Lifesciences Corp's (EW, Financial) average brokerage recommendation is currently 2.5, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Edwards Lifesciences Corp (EW, Financial) in one year is $102.72, suggesting a upside of 43.6% from the current price of $71.53. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Edwards Lifesciences Corp (EW) Summary page.
